[BLPH] Bellerophon Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 24.26 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.54 Change: -0.03 (-5.03%)
Ext. hours: Change: 0 (0%)

chart BLPH

Refresh chart

Strongest Trends Summary For BLPH

BLPH is in the long-term down -67% in 1 year and down -95% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding13.48 M EPS-1.66 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-0.75
P/E To EPS Growth P/S P/BV0.39 Price/Cash Per Share
Price/Free Cash Flow ROA-34.16% ROE-41.16% ROI
Current Ratio5.75 Quick Ratio Long Term Debt/Equity Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities54.91 M Cash From Investing Activities Cash From Operating Activities-8.79 M Gross Profit
Net Profit-12.91 M Operating Profit-14.09 M Total Assets75.18 M Total Current Assets73.57 M
Total Current Liabilities12.79 M Total Debt Total Liabilities12.79 M Total Revenue
Technical Data
High 52 week2.92 Low 52 week0.6 Last close0.66 Last change-0.9%
RSI36.81 Average true range0.03 Beta1.27 Volume449 K
Simple moving average 20 days-2.78% Simple moving average 50 days-18.93% Simple moving average 200 days-52.42%
Performance Data
Performance Week-3.74% Performance Month0.62% Performance Quart-27.02% Performance Half-24.88%
Performance Year-66.96% Performance Year-to-date-17.13% Volatility daily2.12% Volatility weekly4.75%
Volatility monthly9.73% Volatility yearly33.72% Relative Volume232.87% Average Volume426.28 K
New High New Low

News

2019-05-22 08:30:00 | Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease

2019-05-21 08:30:00 | Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference

2019-05-18 09:50:27 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

2019-05-13 08:30:00 | Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference

2019-05-09 08:45:30 | Bellerophon Therapeutics: 1Q Earnings Snapshot

2019-05-09 08:30:00 | Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results

2019-05-03 12:10:01 | What Kind Of Shareholders Own Bellerophon Therapeutics, Inc. NASDAQ:BLPH?

2019-04-08 08:30:00 | Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2019-03-18 14:08:11 | Did Changing Sentiment Drive Bellerophon Therapeutics’s NASDAQ:BLPH Share Price Down A Painful 76%?

2019-03-14 09:09:14 | Bellerophon Therapeutics: 4Q Earnings Snapshot

2019-03-14 08:30:00 | Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

2019-01-28 08:30:00 | Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients  

2019-01-25 16:05:00 | Bellerophon Announces Closing of $7 Million Public Offering of Common Stock

2019-01-23 06:00:00 | Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock

2019-01-22 16:44:28 | Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

2019-01-07 08:30:00 | Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2018-11-21 08:55:00 | Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-07 09:36:38 | Bellerophon Therapeutics: 3Q Earnings Snapshot

2018-11-07 08:30:00 | Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results

2018-10-09 08:30:00 | Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2018-09-10 11:40:00 | 3 Biotech & Marijuana Stocks to Pay Attention to this Quarter

2018-08-29 08:00:00 | Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference

2018-08-20 08:00:00 | Today’s Research Reports on Stocks to Watch:Tesla and Bellerophon Therapeutics

2018-08-08 08:15:42 | The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

2018-08-07 08:30:00 | Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension

2018-08-01 09:16:46 | Bellerophon Therapeutics: 2Q Earnings Snapshot

2018-08-01 08:40:00 | Bellerophon Provides Business Update and Reports Second Quarter 2018 Financial Results

2018-06-15 09:13:01 | 5 Biotech Stocks Under $10 Worthy of Investors' Attention

2018-06-12 08:39:12 | The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp

2018-06-12 08:00:00 | Bellerophon Therapeutics to Participate on Panel at JMP Securities Life Sciences Conference

2018-06-11 12:45:00 | 5 Top-Ranked Small Caps to Buy as Trade Tensions Escalate?

2018-06-11 09:08:01 | Bet on 5 Top-Ranked Small Caps as Trade Tensions Escalate

2018-05-16 08:30:00 | Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference

2018-05-10 08:45:00 | Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results

2018-05-08 08:30:00 | Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

2018-04-30 08:43:12 | Exact Sciences EXAS in Focus: Stock Moves 11.6% Higher

2018-04-19 09:35:00 | 3 Biotech Stocks That Will Thrive Amid Market Instability

2018-04-03 08:30:00 | Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference

2018-03-27 07:00:00 | Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018

2018-03-23 10:56:02 | Will Bellerophon Therapeutics BLPH Continue to Surge Higher?

2018-03-15 19:17:29 | Bellerophon Therapeutics posts 4Q loss

2018-03-15 16:45:00 | Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

2018-01-29 08:30:00 | Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension

2018-01-03 08:30:00 | Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2017-11-30 17:46:13 | Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors

2017-11-07 08:43:18 | Bellerophon Therapeutics posts 3Q loss

2017-11-07 08:30:00 | Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results

2017-09-27 08:30:00 | Bellerophon Announces $23 Million Private Placement

2017-09-07 16:01:00 | Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences

2017-09-05 08:40:17 | Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment